Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 6/20 | 0.50 |
| ▸ | TDO2 | P48775 | 3/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | CNR1 | P21554 | 6/20 | 0.48 |
| ▸ | DRD2 | P14416 | 2/20 | 0.44 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.42 |
| ▸ | RELA | Q04206 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17737066 | 0.90 | IDO1 (0.58) | IDO1TDO2CYP2C9CYP3A4CYP2C8 | |
| SCHEMBL17737538 | 0.90 | IDO1 (0.58) | IDO1TDO2CYP2C9CYP3A4CYP2C8 | |
| SCHEMBL20838737 | 0.90 | IDO1 (0.58) | IDO1TDO2CYP2C9CYP3A4CYP2C8 | |
| SCHEMBL17731108 | 0.79 | IDO1 (0.55) | IDO1TDO2CYP2C9CYP3A4CYP2C8 | |
| SCHEMBL20838627 | 0.78 | IDO1 (0.64) | IDO1TDO2CYP2C9CYP3A4CYP2C8 | |
| SCHEMBL17737121 | 0.78 | IDO1 (0.51) | IDO1TDO2CYP2C9CYP3A4CYP2C8 | |
| SCHEMBL20852663 | 0.78 | IDO1 (0.51) | IDO1TDO2CYP2C9CYP3A4CYP2C8 | |
| SCHEMBL17737122 | 0.78 | IDO1 (0.51) | IDO1TDO2CYP2C9CYP3A4CYP2C8 | |
| SCHEMBL20838723 | 0.78 | IDO1 (0.51) | IDO1TDO2CYP2C9CYP3A4CYP2C8 | |
| SCHEMBL17741156 | 0.77 | IDO1 (0.54) | IDO1TDO2CYP2C9CYP3A4CYP2C8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220274926-A1 | IMMUNOREGULATORY AGENTS | FLEXUS BIOSCIENCES INC (US) | 2022-09-01 | — | — | US | claimed |
| US-11932601-B2 | Immunoregulatory agents | FLEXUS BIOSCIENCES, INC. (US) | 2024-03-19 | — | — | US | disclosed |
| US-20220274926-A1 | IMMUNOREGULATORY AGENTS | FLEXUS BIOSCIENCES INC (US) | 2022-09-01 | — | — | US | disclosed |
| US-11242319-B2 | Immunoregulatory agents | FLEXUS BIOSCIENCES, INC. (US) | 2022-02-08 | — | — | US | disclosed |
| US-20190092729-A1 | IMMUNOREGULATORY AGENTS | FLEXUS BIOSCIENCES, INC. | 2019-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11242319-B2 | Immunoregulatory agents | IDO1, IDO2, INMT | IDO1 1/4885TDO2 5/4885CYP2C9 2655/4885 |
| US-20190092729-A1 | IMMUNOREGULATORY AGENTS | IDO1, IDO2, INMT | IDO1 1/4885TDO2 5/4885CYP2C9 2655/4885 |
| US-11932601-B2 | Immunoregulatory agents | IDO1, IDO2, INMT | IDO1 1/4885TDO2 5/4885CYP2C9 2655/4885 |
| US-20220274926-A1 | IMMUNOREGULATORY AGENTS | IDO1, IDO2, INMT | IDO1 1/4885TDO2 5/4885CYP2C9 2655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.